Tamura M, Yoo Y C, Yoshimatsu K, Yoshida R, Oka T, Ohkuma K, Arikawa J, Azuma I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Vaccine. 1995 Jan;13(1):77-82. doi: 10.1016/0264-410x(95)80015-6.
The ability of two muramyl dipeptide (MDP) derivatives, B30-MDP and MDP-Lys(L18), to enhance the immunogenicity of recombinant hepatitis B surface antigen (rHBsAg) was examined. When mice were immunized intraperitoneally with rHBsAg together with each MDP derivative, the antibody titres were higher than those in mice immunized with alum-adsorbed rHBsAg, which is a commercially available hepatitis B vaccine. When mice were given a subcutaneous or intramuscular injection of rHBsAg and either MDP derivative, the antibody titres were the same as those in mice given alum-adsorbed rHBsAg. These results indicate the usefulness of MDP derivatives as immunoadjuvants for a new-generation vaccine.
研究了两种胞壁酰二肽（MDP）衍生物B30-MDP和MDP-Lys（L18）增强重组乙型肝炎表面抗原（rHBsAg）免疫原性的能力。当用rHBsAg与每种MDP衍生物一起对小鼠进行腹腔免疫时，抗体滴度高于用明矾吸附的rHBsAg免疫的小鼠，明矾吸附的rHBsAg是一种市售的乙型肝炎疫苗。当对小鼠皮下或肌肉注射rHBsAg和任一种MDP衍生物时，抗体滴度与给予明矾吸附的rHBsAg的小鼠相同。这些结果表明MDP衍生物作为新一代疫苗免疫佐剂的有用性。
